Mandate

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

November 12, 2026 Corporate Tax M&A Private Funds

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).

The Fund has secured investment commitments from several prominent investors, including Europeiska Investeringsfonden (EIF), Saminvest, SEB Pension och Försäkring and SEB-Stiftelsen.

The Fund invests in early-stage companies driving the energy and resource transition, companies where the positive impact grows with their business. The Fund follows the successful deployment of the first fund, which has backed 16 companies. To date, the new fund has invested in seven companies within energy, electrification, industrial optimisation and resource-smart solutions.

Vinge’s team primarily consisted of Mattias Schömer, Martin Cronsioe, Sara Link, Nils Unckel, Mikaela Reinhammar, Emelie Svanberg, Erik Kochbati, Felicia Andersson and Emelie Zingmark.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026